29-08-2019 дата публикации
Номер: US20190264154A1
A method for improving productivity in microbial fermentations and mammalian cell culture bioreactors. 2. The method of claim 1 , wherein the product is selected from a biopolymer.3E. coli, Bacillus,Saccharomyces, Pichia, Aspergillus, Fusarium, Kluyveromyces,. The method of claim 2 , wherein the biopolymer is expressed by at least one cell selected from the group consisting of yeast from the genus of CHO (Chinese Hamster Ovary) cell claim 2 , hybridomas claim 2 , BHK (Baby Hamster Kidney) cell claim 2 , myeloma cell claim 2 , HEK-293 cell claim 2 , human lymphoblastoid cell claim 2 , a human cell and a mouse cell.4. The method of claim 2 , wherein the biopolymer is a polypeptide or protein.5. The method of claim 4 , wherein the polypeptide is an antibody or fragment thereof claim 4 , Human growth hormone claim 4 , Follicle-stimulating hormone claim 4 , Factor VIII claim 4 , Factor VII claim 4 , Factor IX Erythropoietin (EPO) claim 4 , Granulocyte colony-stimulating factor (G-CSF) claim 4 , alpha-glactosidase A claim 4 , alpha-L-iduronidase (rhIDU; laronidase) claim 4 , N-acetylgalactosamine-4-sulfatase (rhASB; galsulfase) claim 4 , DNAse claim 4 , Tissue plasminogen activator (TPA) claim 4 , Glucocerebrosidase claim 4 , Interferon (IF) claim 4 , Insulin claim 4 , Insulin derivative claim 4 , Insulin-like growth factor 1 claim 4 , Tenecteplase claim 4 , antihemophilic factor claim 4 , human coagulation factor claim 4 , Etanercept claim 4 , Trastuzumab claim 4 , Infliximab claim 4 , Basiliximab claim 4 , Belimumab claim 4 , Daclizumab claim 4 , Adalimumab Abciximab or claim 4 , Afutuzumab claim 4 , Alemtuzumab claim 4 , Cetuximab claim 4 , Daclizumab claim 4 , Denosumab claim 4 , Eculizumab claim 4 , Edrecolomab claim 4 , Golimumab claim 4 , Ibritumomab tiuxetan claim 4 , Mepolizumab claim 4 , Motavizumab claim 4 , Natalizumab claim 4 , Ofatumumab claim 4 , Omalizumab claim 4 , Oregovomab claim 4 , Palivizumab claim 4 , Pemtumomab claim 4 , Pertuzumab claim 4 , ...
Подробнее